N-苄基吡咯烷-3-甲酸甲酯 | 17012-21-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-苄基吡咯烷-3-甲酸甲酯
• 中文别名: N-苄基吡咯烷-3-羧酸甲酯；1-苄基吡咯烷-3-羧酸甲酯；N-苄基-3-吡咯烷甲酸甲酯
• 英文名称: 1-benzylpyrrolidine-3-carboxylic acid methyl ester
• 英文别名: methyl 1-benzylpyrrolidine-3-carboxylate
• CAS: 17012-21-4
• 化学式: C₁₃H₁₇NO₂
• mdl: MFCD04038678
• 分子量: 219.283
• InChiKey: GDWFCUOFVSNTTG-UHFFFAOYSA-N

物化性质

• 沸点：
  98℃/0.2mm
• 密度：
  1.08

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl n-benzyl-3-pyrrolidinecarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl n-benzyl-3-pyrrolidinecarboxylate
CAS number: 17012-21-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H17NO2
Molecular weight: 219.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-苄基吡咯烷-3-甲酸甲酯 在 palladium dihydroxide sodium hydroxide 、 氢气 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 10.0h， 生成 1-BOC-吡咯烷-3-甲酸
  参考文献：
  名称：

  新颖的基于磷自由基的途径制备霍索菲林。

  摘要：

  [反应：请参见文字]。源自磷试剂的自由基，次磷酸乙基哌啶（EPHP）和二乙基氧化膦（DEPO）被用于两种合成生物碱霍菲林的相关方法中（1）。特别地，事实证明，DEPO对于在80摄氏度下实现Bu（3）SnH难以或不可能实现的环化是有益的。

  DOI：

  10.1021/ol051095i
• 作为产物：
  描述：

  衣康酸二甲酯 在 9-硼双环[3.3.1]壬烷 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N-苄基吡咯烷-3-甲酸甲酯
  参考文献：
  名称：

  通过β-和γ-氨基酸的自由基脱羧合成官能化氮杂环

  摘要：

  通过β-和γ-氨基酸的自由基脱羧获得碘化或氧化氮杂环。这种温和、通用的反应可用于合成生物活性产品，如 4-芳基哌啶、羟基化哌啶和新型抗真菌剂。

  DOI：

  10.1002/ejoc.200400698

文献信息

• N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
  申请人：——

  公开号：US20020165241A1

  公开（公告）日：2002-11-07

  Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  由化学式（I）表示的化合物及其药学上可接受的盐，可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer
  作者：Rui Min、Weibin Wu、Mingzhong Wang、Lin Tang、Dawei Chen、Huan Zhao、Cunlong Zhang、Yuyang Jiang

  DOI：10.3390/molecules24101901

  日期：——

  A series of benzimidazole carboxamide derivatives have been synthesized and characterized by 1H-NMR, 13C-NMR and HRMS. PARP inhibition assays and cellular proliferation assays have also been carried out. Compounds 5cj and 5cp exhibited potential anticancer activities with IC50 values of about 4 nM against both PARP-1 and PARP-2, similar to the reference drug veliparib. The two compounds also displayed

  合成了一系列苯并咪唑甲酰胺衍生物，并通过1H-NMR、13C-NMR和HRMS对其进行了表征。还进行了 PARP 抑制试验和细胞增殖试验。化合物 5cj 和 5cp 表现出潜在的抗癌活性，对 PARP-1 和 PARP-2 的 IC50 值为约 4 nM，类似于参考药物 veliparib。这两种化合物对 MDA-MB-436 和 CAPAN-1 细胞系的体外细胞毒性也比 veliparib 和 olaparib 略好，分别为 17.4 µM 和 11.4 µM、19.8 µM 和 15.5 µM。还讨论了基于分子对接的构效关系。
• Aromatic amides
  申请人：Eli Lilly and Company

  公开号：US06635657B1

  公开（公告）日：2003-10-21

  This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

  本申请涉及式I化合物（或其药用可接受的盐），如本文所述，其药物组合物，及其作为因子Xa抑制剂的用途，以及其制备过程和中间体。
• Facile reduction of tertiary lactams to cyclic amines with 9-borabicyclo[3.3.1]nonane (9-BBN)
  作者：Christopher J. Collins、Marc Lanz、Bakthan Singaram

  DOI：10.1016/s0040-4039(99)00556-0

  日期：1999.5

  Various 5- and 6-membered tertiary lactams were reduced to the corresponding cyclic tertiary amines using 2.2 to 2.5 equivalents of 9-borabicyclo[3.3.1]nonane (9-BBN). This method is highly chemoselective and it is easy to reduce a lactam in the presence of an ester.

  使用2.2至2.5当量的9-硼环[3.3.1]壬烷（9-BBN）将各种5元和6元叔内酰胺还原为相应的环状叔胺。该方法是高度化学选择性的，并且在酯的存在下容易还原内酰胺。
• 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS
  申请人：MISSION THERAPEUTICS LIMITED

  公开号：US20200331888A1

  公开（公告）日：2020-10-22

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R 1a , R 1b , R 1c , R 1d , R 1e and R 1f each independently represent hydrogen, optionally substituted C 1 -C 6 alkyl or optionally substituted C 3 -C 4 cycloalkyl, or R 1b and R 1c together form an optionally substituted C 3 -C 6 cycloalkyl ring, or R 1d and R 1e together form an optionally substituted C 3 -C 6 cycloalkyl ring; R 2 represents hydrogen or optionally substituted C 1 -C 6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

  本发明涉及新化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C-末端水解酶30或泛素特异性肽酶30（USP30）。这些新化合物的化学式为（I）：（化学式（I）），或其药学上可接受的盐，其中：R1a，R1b，R1c，R1d，R1e和R1f分别独立地代表氢，可选择地取代的C1-C6烷基或可选择地取代的C3-C4环烷基，或者R1b和R1c共同形成一个可选择地取代的C3-C6环烷基环，或者R1d和R1e共同形成一个可选择地取代的C3-C6环烷基环；R2代表氢或可选择地取代的C1-C6烷基；A代表一个可选择地进一步取代的5到10个成员的单环或双环杂环芳基，杂环烷基或芳基环；L代表一个共价键或连接物；B代表一个可选择地取代的3到10个成员的单环或双环杂环烷基，杂环芳基，环烷基或芳基环；当-A-L-B位于位置x时，通过A的一个碳环原子连接到A，且：A不能是三唑吡啶基，三唑吡啉基，咪唑三嗪基，咪唑吡嗪基或吡咯嘧啶基；或者B不能被苯氧基取代；或者当L是氧原子时，B不能是环戊基。